CoChat
Sign Up
Cited by 1,041Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

Open access
Avenell, A, Broom, J, Brown, T, Poobalan, A, Aucott, L, Stearns, S, Smith, W, Jung, R +2 more·2004·Health Technology Assessment
DOI 10.3310/hta8210
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVES: To undertake a systematic review of the long-term effects of obesity treatments on body weight, risk factors for disease, and disease. METHODS: The study encompassed three systematic reviews that examined different aspects of obesity treatments. (1) A systematic review of obesity treatments in adults where the methods of the Cochrane Collaboration were applied and randomised controlled trials (RCTs) with a follow-up of at least 1 year were evaluated. (2) A systematic epidemiological review, where studies were sought on long-term effects of weight loss on morbidity and/or mortality, and examined through epidemiological modelling. (3) A systematic economic review that sought reports with both costs and outcomes of treatment, including recent reports that assessed the cost-effectiveness of pharmaceutical and surgical interventions. A Markov model was also adopted to examine the cost-effectiveness of a low-fat diet and exercise intervention in adults with obesity and impaired glucose tolerance. RESULTS: The addition of the drugs orlistat or sibutramine was associated with weight loss and generally improved risk factors, apart from diastolic blood pressure for sibutramine. Metformin was associated with decreased mortality after 10 years in obese people with type 2 diabetes. Low-fat diets were associated with continuing weight loss for 3 years and improvements in risk factors, as well as prevention of type 2 diabetes and improved control of hypertension. Insufficient evidence was available to demonstrate the benefits of low calorie or very low calorie diets. The addition of an exercise or behaviour programme to diet was associated with improved weight loss and risk factors for at least 1 year. Studies combining low-fat diets, exercise and behaviour therapy suggested improved hypertension and cardiovascular disease. Family therapy was associated with improved weight loss for 2 years compared to individual therapy. There was insufficient evidence to conclude that individual therapy was more beneficial than group therapy. Weight lost more quickly (within 1 year), from the epidemiology review, may be more beneficial with respect to the risk of mortality. The effects of intentional weight loss need further investigation. Weight loss from surgical and non-surgical interventions for people suffering from obesity was associated with decreased risk of development of diabetes, and a reduction in low-density lipoprotein cholesterol, total cholesterol and blood pressure, in the long term. Targeting high-risk individuals with drugs or surgery was likely to result in a cost per additional life-year or quality-adjusted life-year (QALY) of no more than 13,000 British pounds. There was also suggestive evidence of cost saving from treatment of people with type 2 diabetes with metformin. Targeting surgery on people with severe obesity and impaired glucose tolerance was likely to be more cost-effective at 2329 British pounds per additional life-year. Economic modelling over 6 years for diet and exercise for people with impaired glucose tolerance was associated with a high initial cost per additional QALY, but by the sixth year the cost per QALY was 13,389 British pounds. Results did not include cost savings from diseases other than diabetes, and therefore may be conservative. CONCLUSIONS: The drugs orlistat and sibutramine appear beneficial for the treatment of adults with obesity, and metformin for obese patients with type 2 diabetes. Exercise and/or behaviour therapy appear to improve weight loss when added to diet. Low-fat diets with exercise, or with exercise and behaviour therapy are associated with the prevention of type 2 diabetes and hypertension. Long-term weight loss in epidemiological studies was associated with reduced risk of type 2 diabetes, and may be beneficial for cardiovascular disease. Low-fat diets and exercise interventions in individuals at risk of obesity-related illness are of comparable cost to drug treatments. Long-term pragmatic RCTs of obesity treatments in populations with obesity-related illness or at high risk of developing such illness are needed (to include an evaluation of risk factors, morbidity, quality of life and economic evaluations). Drug trials that include dietary advice, plus exercise and/or behaviour therapy are also needed. Research exploring effective types of exercise, diet or behaviour and also interventions to prevent obesity in adults is required.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta8210

Cites

450 of 450 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

1 retracted

Flagged first, then by citations

164 of the 614 references couldn’t be matched to a known paper.

Research works printed but not linked: 267

  1. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? BMJ 1995;311:437-9.
  2. Grio R, Porpiglia M. Obesity: internal medicine, obstetric and gynaecological problems related to overweight. Panminerva Med 1994;36:138-41.
  3. Parsons T, Power C, Logan S, Summerbell C. Childhood predictions of adult obesity: a systematic review. Int J Obes 1999;23(Suppl):S1-107.
  4. Flegal KM, Troiano RP, Pamuk E, Kuczmarski RJ, Campbell G. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995;333:1165-70.
  5. Stunkard AJ, Sorensen TI, Hanis C, Teasdale TW, Chakraborty R, Schull WJ, et al. An adoption study of human obesity. N Engl J Med 1986;314:193-8.
  6. Stunkard AJ, Sorensen TI, Schulsinger F. Use of the Danish adoption register for the study of obesity and thinness. In Kety S, editor. The genetics of neurological and psychiatric disorders. New York: Raven Press; 1983. pp. 115-20.
  7. Thorkild I, Sorenson A, Stunkard AJ. Overview of the adoption studies. In: Bouchard C, editor. The genetics of obesity. Boca Raton, FL: CRC Press; 1994. pp. 42-61.
  8. Yeo GR, Farooqui IA, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S. Frameshift mutation in MC4R associated with dominantly inherited obesity. Nat Genet 1998;20:111-12.
  9. Bouchard C. Genetics of obesity: overview and research directions. In Bouchard C, editor. The genetics of obesity. Boca Raton, FL: CRC Press; 1994. pp. 223-33.
  10. Lissner L, Heitmann BL. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr 1995; 49:79-90.
  11. Sempos CT, Durazo-Arvizu R, McGee DL, Cooper RS, Prewitt TE. The influence of cigarette smoking on the association between body weight and mortality. The Framingham Heart Study revisited. Ann Epidemiol 1998;8:289-300.
  12. Colditz GA, Willett WC, Rotnetzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
  13. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5(18). References
  14. Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6(12).
  15. NHS Centre for Reviews and Dissemination. A systematic review of the interventions for the prevention and treatment of obesity, and the maintenance of weight loss. NHS CRD Report No. 10. York: University of York; 1997.
  16. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.15 [updated April 2002]. In The Cochrane Library (Issue 2). Oxford: Update Software; 2002. Updated quarterly.
  17. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat diets for reducing obesity (Cochrane Review). In The Cochrane Library (Issue 4). Oxford: Update Software; 2002.
  18. Broom I, Wilding J, Stott P, Myers N, UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002;56:494-9.
  19. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes 2000;24:306-13.
  20. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997;21:S24-30.
  21. Lindgarde F, on behalf of the Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000;248:245-54.
  22. Broom I, Hughes E, Dodson P, Reckless J, on behalf of the Orlistat UK Study Group. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 2002;9(8):460-8.
  23. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
  24. Smith IG, on behalf of the Sibutramine Clinical Study. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.
  25. Toubro S, Hilsted J, Astrup A, for the STORM Study Group. Effekt af sibutramin til vaegttabsvedligeholdelse. En randomiseret klinisk kontrolleret undersogelse [in Danish]. Ugeskr Laeger 2001;163:2935-40.
  26. Mertens I, Wauters M, Peiffer F. A 2 year combined weight loss program with a hypocaloric diet, sibutramine and physical activity increases antithrombin III levels in obese subjects. Obes Res 1999;7:125.
  27. James WPT, Astrup A, Finer N, on behalf of the STORM Group. Drug therapy for management of obesity. Lancet 2001;357:1287-8.
  28. Bitsch M, Skrumsager BK. Femoxetine in the treatment of obese patients in general practice. Int J Obes 1987;11:183-90.
  29. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin- dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995;44:1570-6.
  30. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 1993;18:129-35.
  31. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge- eaters and non-binge-eaters. Am J Psychiatry 1990; 147:876-81.
  32. Darga LL, Lucas CP, Carroll-Michals L. The effect of fluoxetine, a serotonin-uptake inhibitor, on weight loss in obese subjects. Am J Clin Nutr 1988; 47:764.
  33. Wadden TA, Bartlett SJ, Foster G. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res 1995;3:549-57.
  34. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998;21:1967-72.
  35. Fontbonne A, Andre P, Eschwege E. BIGPRO (Biguanides and the Prevention of the Risk of Obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metabolisme 1991;17:249-54.
  36. Teupe B, Bergis K. Prospective randomized two- years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metabolisme 1991;17:213-17.
  37. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non- insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
  38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). [published erratum appears in Lancet 1998; 352:1557]. Lancet 1998;352:854-65.
  39. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS no. 51). Diabetologia 2001;44:298-304.
  40. Turner R, Murchison L, Wright AD, Oakley N, Kohner E, Hayes R, et al. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-75.
  41. Turner RC, Mann JI, Iceton G. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983; 24:404-11.
  42. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005-12.
  43. Wright AD, Cull CA, Holman RR, Turner RC. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea- treated type 2 diabetes. Diabetes Care 1998; 21:87-92.
  44. UK Prospective Diabetes Study Group UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. [published erratum appears in Diabetes 1996;45:1655]. Diabetes 1995;44:1249-58.
  45. Chiasson JL. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121:928-35.
  46. Rodger NW. Clinical experience with acarbose: results of a Canadian multicentre study. Clin Invest Med 1995;18:318-24.
  47. Wolever TMS. One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 1995;12:164-72.
  48. Wolever TMS. No relationship between carbohydrate intake and effect of acarbose on HbA 1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Diabetes Care 1998;21:1612-18.
  49. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309:1589-92.
  50. Anon. Popular diets: a scientific review. Obes Res 2001; 9(Suppl
  51. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1:113-19.
  52. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycaemic control and body mass in type 2 diabetes mellitus. A meta-analysis of controlled clinical trials. JAMA 2001;286:1218-27.
  53. Douketis JD, Feightner JW, Attia J, Feldman WF, with the Canadian Task Force on Preventive Health Care. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. CMAJ 1999; 160:513-25.
  54. Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non- pharmacological interventions. J Public Health Med 1998;20:441-8.
  55. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Clements G, Capps N, et al. Reducing or modified dietary fat for preventing cardiovascular disease (Cochrane Review). In The Cochrane Library (Issue 1). Oxford: Update Software; 2002.
  56. Johanesen K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999;22:33-7.
  57. Kushner RF, Foster GD. Obesity and quality of life. Nutrition 2000;16:947-52.
  58. Pirozzo S, Cameron C, Glasziou P, Summerbell C. Advice on low-fat diets for reducing obesity (Protocol for a Cochrane Review). In The Cochrane Library (Issue 1). Oxford: Update Software; 2002.
  59. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health- related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manage Care 2001;7:926-7.
  60. Sayler ME, Goldstein DJ, Roback PJ, Atkinson RL. Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. Int J Obes 1994;18:742-51.
  61. Summerbell CD, Jones LV, Glasziou P. The long-term effect of advice on low-fat diets in terms of weight loss: an interim meta-analysis. J Hum Nutr Diet 1998; 11:209-17.
  62. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998;316:1213-20.
  63. Thompson RL, Summerbell CD, Hooper L, Higgins JP, Little PS, Talbot D, et al. Dietary advice given by a dietitian versus other health professional or self-help resources to reduce blood cholesterol (Cochrane Review). In The Cochrane Library (Issue 1). Oxford: Update Software; 2002.
  64. Thorogood M. Combining diet with physical activity in the treatment of obesity. J Hum Nutr Diet 1998; 11:239-42.
  65. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
  66. Fontbonne A, Andre P, Eschwege E. BIGPRO (Biguanides and the Prevention of the Risk of Obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metabolisme 1991;17:249-54.
  67. Bard JM, Charles MA, Juhan-Vague I, Vague P, Andre P, Safar M, et al. Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. Arterioscler Thromb Vasc Biol 2001; 21:407-14.
  68. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998;21:1967-72.
  69. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19:920-6.
  70. Bitsch M, Skrumsager BK. Femoxetine in the treatment of obese patients in general practice. Int J Obes 1987; 11:183-90.
  71. Black DR, Lantz CE. Spouse involvement and a possible long-term follow-up trap in weight loss. Behav Res Ther 1984;22:557-62.
  72. Blonk MC, Jacobs MAJM, Biesheuvel EHE, Weeda- Mannak WL, Heine RJ. Influence on weight loss in type 2 diabetic patients: little long-term benefit from group behaviour therapy and exercise training. Diabet Med 1994;11:449-57.
  73. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long- term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995;44:1570-6.
  74. Broom, 2001a (published and unpublished data) *Broom I, Wilding J, Stott P, Myers N, on behalf of the UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002;56:494-9.
  75. Broom I, Hughes E, Dodson P, Reckless J, on behalf of the Orlistat UK Study Group. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 2001;9:460-8.
  76. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994;121:928-35.
  77. Rodger NW, Chiasson J-L, Josse RG, Hunt JA, Palmason C, Ross SA, et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clin J Invest Med 1995;18:318-24.
  78. Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non- insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997;21:756-63.
  79. Wolever TMS, Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. No relationship between carbohydrate intake and effect of acarbose on HbA 1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Diabetes Care 1998;21:1612-18.
  80. Wolever TMS, Radmard R, Chiasson J-L, Hunt JA, Josse RG, Palmason C, et al. One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 1995;12:164-72.
  81. Tuomilehto J, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-50.
  82. Finer, 2000 (published data only) *Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes 2000;24:306-13.
  83. Frey-Hewitt B, Vranizan KM, Dreon DM, Wood PD. The effect of weight loss by dieting or exercise on resting metabolic rate in overweight men. Int J Obes 1990; 14:327-34.
  84. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 1994; 18:129-35.
  85. Darga LL, Lucas CP, Carrol-Michels L. The effect of fluoxetine, a serotonin-uptake inhibitor, on weight loss in obese subjects. Am J Clin Nutr 1988;47:764.
  86. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991;54:321-5.
  87. Hakala P, Karvetti RL. Weight reduction on lactovegetarian and mixed diets. Changes in weight, nutrient intake, skinfold thicknesses and blood pressure. Eur J Clin Nutr 1989;43:421-30.
  88. Hakala P. Weight reduction programme based on dietary and behavioural counselling -a 2-year follow-up study. Int J Obes 1993;17:49.
  89. Marniemi J, Seppanen A, Hakala P. Long-term effects on lipid metabolism of weight reduction on lactovegetarian and mixed diet. Int J Obes 1990; 14:113-25.
  90. Hakala P, Karvetti R-L, Ronnemaa T. Groups vs. individual weight reduction programmes in the treatment of severe obesity -a five year follow-up study. Int J Obes 1993;17:97-102.
  91. Hankey CR, Leslie WS, Lean MEJ. An energy deficit approach to weight management during nutritional counselling post myocardial infarction. Proc Nutr Soc 2001;60:33A.
  92. Leslie WS, Hankey CR, Currall JE, Matthews D, Lean ME. The impact of a transferable programme of intensified nutritional counselling in cardiac rehabilitation following myocardial infarction. Proc Nutr Soc 2000;59: 69A.
  93. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9(2):160-7.
  94. Hauptman J, Lucas C, Boldrin M, Segal KR. Long-term weight loss with orlistat: impact of selection algorithm on outcomes. Obes Res 1999;7(Suppl 1):50S. interventions in Pima Indians: a pilot study. Diabet Med 1998;15:66-72.
  95. Anderssen SA, Haaland A, Hjermann I, Urdal P, Gjesdal K, Holme I. Oslo Diet and Exercise Study: a one-year randomized intervention trial. Effect on hemostatic variables and other coronary risk factors. Nutr Metab Cardiovasc Dis 1995;5:189-200.
  96. Anderssen SA, Hjermann I, Urdal P, Torjesen PA, Holme I. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the 'atherothrombogenic syndrome'. Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med 1996;240:203-9.
  97. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994;11:105-10.
  98. Ost LG, Gotestam KG. Behavioral and pharmacological treatments for obesity: an experimental comparison. Addict Behav 1976;1:331-8.
  99. Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr 1989;49:1115-23.
  100. Pearce JW, LeBow MD, Orchard J. Role of spouse involvement in the behavioral treatment of overweight women. J Consult Clin Psychol 1981;49:236-44.
  101. Phenix A. A one year follow-up of a weight loss study comparing behavioral techniques, nutrition information and exercise [PhD thesis]. Fresno, CA: California School of Professional Psychology; 1990.
  102. Pritchard JE. The body composition diet and exercise study: the effect of weight loss on soft tissue composition [Thesis]. Melbourne: University of Melbourne; 1995.
  103. Pritchard JE, Nowson CA, Wark JD. Bone loss accompanying weight loss: a randomised controlled weight loss study using diet and exercise. Proc Nutr Soc Aust 1995;19:57.
  104. Pritchard JE, Saul ALF, Nowson CA, Wark JD. Body composition following diet-induced and/or exercise- induced weight loss: A randomised controlled study. Int J Obes 1995;19:212.
  105. Pritchard JE, Nowson CA, Wark JD. Bone loss accompanying diet-induced or exercise-induced weight loss: a randomised controlled study. Int J Obes 1996; 20:513-20.
  106. Pritchard DA, Hyndman J, Taba F. Nutritional counselling in general practice: a cost effective analysis. J Epidemiol Community Health 1999;53:311-16.
  107. Rosenthal B, Allen GJ, Winter C. Husband involvement in the behavioral treatment of overweight women: initial effects and long-term follow-up. Int J Obes 1980; 4:165-73.
  108. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61.
  109. Toornvliet AC, Pijl H, Frolich M, Westendorp RGJ, Meinders AE. Insulin and leptin concentrations in obese humans during long-term weight loss. Neth J Med 1997; 51:96-102.
  110. Sikand G, Kondo A, Foreyt JP, Jones PH, Gotto AM. Two-year follow-up of patients treated with a very-low- calorie diet and exercise training. J Am Diet Assoc 1988; 88:487-8.
  111. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo- controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72.
  112. Franson K, Rossner S. Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor. J Intern Med 2000;247:607-14.
  113. Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes 2000;24:1567-72.
  114. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes 2001; 25:212-18.
  115. Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MI. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharamcol Ther 1999;66:315-22.
  116. Smith, 2001a (10 mg sibutramine vs placebo) Smith, 2001b (15 mg sibutramine vs placebo) *Smith IG, on behalf of the members of the Sibutramine Clinical Study 1047 Team, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.
  117. Jones SP, Smith IG, Kelly F, Gray JA. Long term weight loss with sibutramine. Int J Obes 1995;19:41.
  118. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study [published erratum in BMJ 2000;320:984]. BMJ 2000;320:827-32.
  119. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25.
  120. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al., for the STORM Study Group. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int J Obes 2001; 25:496-501.
  121. James P, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Sibutramine Trial in Obesity Reduction and Maintenance (STORM). Obes Res 1999;7:50.
  122. Mertens I, Wauters M, Peiffer F, Van de Sompel M, Van der Planken B, Corthouts B, et al. A 2 year combined weight loss program with a hypocaloric diet, sibutramine and physical activity increases antithrombin III levels in obese subjects. Obes Res 1999;7:125.
  123. Toubro S, Hansen DL, Hilsted JC, Porsborg PA, Astrup AV, for the STORM Study Group. Effekt af sibutramin til vaegttabsvedligeholdelse. En randomiseret klinisk kontrolleret undersogelse. Ugeskr Laeger 2001;163:2935-40.
  124. Straw, 1983 (published data only) Straw, 1983a (weigh-in maintenance) Straw, 1983b (individual problem-solving maintenance) Straw MK, Terre L. An evaluation of individualized behavioral obesity treatment and maintenance strategies. Behav Ther 1983;14:255-66.
  125. Swinburn BA, Metcalf P, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001;24:619-24.
  126. Davis BR, Blaufox MD, Oberman A, Wassertheil- Smoller S, Zimbaldi N, Cutler JA, et al. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1993;153:1773-82.
  127. Davis BR, Oberman A, Blaufox MD, Wassertheil- Smoller S, Zimbaldi N, Kirchner K, et al. Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. Am J Hypertens 1994;7:926-32.
  128. Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, et al., for the TAIM Research Group. Effect of antihypertensives in sexual function and quality of life: the TAIM study. Ann Intern Med 1991;114:613-20.
  129. Teupe B, Bergis K. Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metabolisme 1991;17:213-17.
  130. TOHP I, 1992 (published data only) *Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. JAMA 1992;267:1213-20.
  131. Satterfield S, Cutler JA, Langford HG, Applegate WB, Borhani NO, Brittain E, et al., for the Trials of Hypertension Prevention Collaborative Research Group. Trials of Hypertension Prevention. Phase I design. Ann Epidemiol 1991;1(5):455-71.
  132. TOHP, II 1997 (published data only) *Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high- normal blood pressure. The Trials of Hypertension Prevention, Phase II. Arch Intern Med 1997;157:657-67.
  133. Appel LJ, Hebert PR, Cohen JD, Obarzanek E, Yamamoto M, Buring J, et al. Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995;5:149-55.
  134. Hebert PR, Bolt RJ, Borhani NO, Cook NR, Cohen JD, Cutler JA, et al. Design of a multicenter trial to evaluate long-term life-style intervention in adults with high- normal blood pressure levels. Trials of Hypertension Prevention (phase II). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995;5:130-9.
  135. Lasser VI, Raczynski JM, Stevens VJ, Mattfeldt-Beman MK, Kumanyika S, Evans M, et al. Trials of Hypertension Prevention, Phase II. Structure and content of the weight loss and dietary sodium reduction interventions. Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995;5:156-64.
  136. Anderson RT, Hogan P, Rosen R, Shumaker SA. Baseline correlates with quality of life among men and women with medication-controlled hypertension. The Trial of Nonpharmacologic Interventions in the Elderly (TONE). J Am Geriatr Soc 1997;45:1080-5.
  137. Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001;161:685-93.
  138. Bahnson JL, Whelton PK, Appel LJ, Espeland MA, Wofford JL, Rosen R, et al. Baseline characteristics of randomized participants in the Trial of Nonpharmacologic Intervention in the Elderly (TONE). Dis Manage Clin Outcomes 1997;1:61-8.
  139. Chao D, Espeland MA, Farmer D, Register TC, Lenchik L, Applegate WB, et al. Effect of voluntary weight loss on bone mineral density in older and overweight women. J Am Geriatr Soc 2000;48:753-9.
  140. Espeland MA, Whelton PK, Kostis JB, Bahnson JL, Ettinger WH, Cutler JA, et al. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. TONE Cooperative Research Group. Trial of Nonpharmacologic Interventions in the Elderly. Arch Fam Med 1999;8:228-36.
  141. Kostis JB, Espeland MA, Appel L, Johnson KC, Pierce J, Wofford JL. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Trial of Nonpharmacologic Interventions in the Elderly (TONE) Cooperative Research Group. Am J Cardiol 1998;82:1501-8.
  142. Wilson A, Kostis J, Philipp C, Appel L, Espeland M, Johnson K, et al. ACE gene (DD) genotype is associated with response to dietary weight loss therapy of hypertension: effect of race and sex. J Hypertens 2000; 18:S124.
  143. Torgerson JS, Lissner L, Lindroos AK, Kruijer H, Sjostrom L. VLCD plus dietary and behavioural support versus support alone in the treatment of severe obesity. A randomised two-year clinical trial. Int J Obes 1997; 21:987-94.
  144. Tucker JA, Samo JA, Rand CS, Woodward ER. Behavioral interventions to promote adaptive eating behavior and lifestyle changes following surgery for obesity: results of a two-year evaluation. Int J Eat Disord 1991;10:689-98. UKPDS (published data only) *UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published erratum in Lancet 1998;352:1557]. Lancet 1998;352:854-65.
  145. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al. Cost-effectiveness analysis of intensive blood- glucose control with metformin in overweight patients with type II diabetes (UKPDS no. 51). Diabetologia 2001; 44:298-304.
  146. Turner RC, Mann JI, Iceton G. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983;24:404-11.
  147. Turner RC, Holman RR, Mathews DR, Oakes SF, Bassett PA, Stratton IM, et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.
  148. Turner R, Murchison L, Wright AD, Oakley N, Kohner E, Hayes R, et al. United Kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-75.
  149. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
  150. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. [published erratum in Diabetes 1996;45:1655]. Diabetes 1995;44:1249-58.
  151. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
  152. Waard FD, Ramlau R, Mulders Y, Vries TD, Waveren SV. A feasibility study on weight reduction in obese postmenopausal breast cancer patients. Eur J Cancer Prev 1993;2:233-8.
  153. Wadden TA, Stunkard AJ, Day SC, Gould RA, Rubin CJ. Less food, less hunger: reports of appetite and symptoms in a controlled study of a protein-sparing modified fast. Int J Obes 1987;11:239-49.
  154. Wadden TA, Stunkard AJ, Liebschutz J. Three-year follow-up of the treatment of obesity by very low calorie diet, behavior therapy, and their combination. J Consult Clin Psychol 1988;56:925-8.
  155. Foster GD, Wadden TA, Kendall PC, Stunkard AJ, Vogt RA. Psychological effects of weight loss and regain: a prospective evaluation. J Consult Clin Psychol 1996; 64:752-7.
  156. Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, et al. Sertraline and relapse prevention training following treatment by very-low- calorie diet: a controlled clinical trial. Obes Res 1995; 3:549-57.
  157. Foster GD, Wadden TA, Peterson FJ, Leitizia KA, Bartlett SJ, Conill AM. A controlled comparison of three very- low-calorie diets: effects on weight, body composition, and symptoms. Am J Clin Nutr 1992;55:811-17.
  158. Wadden, 1998c (aerobic and strength exercise) *Wadden TA, Vogt RA, Foster GD, Anderson DA. Exercise and the maintenance of weight loss: 1-year follow-up of a controlled clinical trial. J Consult Clin Psychol 1998;66:429-33.
  159. Ashutosh K, Methrotra K, Fragale-Jackson J. Effect of sustained weight loss and exercise on aerobic fitness in obese women. J Sports Med Phys Fitness 1997;37:252-7.
  160. Wing, 1984 (published data only) Wing, 1984a (concentrated behavioural booster sessions) Wing, 1984b (spaced behavioural booster sessions) Wing RR, Epstein LH, Marcus MD, Koeske R. Intermittent low-calorie regimen and booster sessions in the treatment of obesity. Behav Res Ther 1984;22:445-9.
  161. Wing RR, Epstein LH, Paternostro-Bayles M, Kriska A, Nowalk MP, Gooding W. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1988; 31:902-9.
  162. Wing RR, Marcus MD, Epstein LH, Jawad A. A 'family- based' approach to the treatment of obese type II diabetic patients. J Consult Clin Psychol 1991;59:156-62.
  163. Wing RR, Jeffery RW. Benefits of recruiting participants with friends and increasing social support for weight loss and maintenance. J Consult Clin Psychol 1999; 67:132-8.
  164. Fortmann SP, Haskell WL, Wood PD, Stanford Weight Control Project. Effects of weight loss on clinic and ambulatory blood pressure in normotensive men. Am J Cardiol 1988;62(1):89-93.
  165. Williams PT, Stefanick ML, Vranizan KM, Wood PD. The effects of weight loss by exercise or by dieting on plasma high-density lipoprotein (HDL) levels in men with low, intermediate, and normal-to-high HDL at baseline. Metabolism 1994;43:917-24.
  166. Wood, 1991 (published data only) Wood, 1991a (females) Wood, 1991b (males) *Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight- reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991;325:461-6.
  167. Wood, PD, Stefanick ML, Haskell WL. Exercise offsets adverse lipoprotein effects of a 'heart healthy' diet for weight loss. Arteriosclerosis 1989;9:773A.
  168. Adachi Y. The effect of behavioral treatment of obesity and correlates of weight loss in treatment and at 2-year follow-up. Jpn J Behav Ther 1989;15:36-55 (BMI not ≥ 28 kg/m
  169. Agewall S, Fagerberg B, Berglund G, Schmidt C, Wendelhag I, Wikstrand J, et al. Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. J Intern Med 2001;249:305-14 (BMI not ≥ 28 kg/m
  170. Allison TG, Farkouh ME, Smars PA, Evans RW, Squires RW, Gabriel SE, et al. Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a chest pain evaluation in the emergency room [CHEER] substudy). Am J Cardiol 2000;86:133-8 (6 months).
  171. Amato S, Colajanni E, Averna MR, Barbagallo CM, Lo Cascio ML, Traina G, et al. Diet and psychological therapy in a group of severely obese patients [in Italian]. Minerva Endocrinol 1990;15:219-21 (9 months).
  172. Andersen T, Hyldstrup L, Quaade F. Formula diet in the treatment of moderate obesity. Int J Obes 1983;7:423-30 (36 weeks).
  173. Bahadori B, Smolle KH, Habersack-Wallner S, Toplak H, Wascher TC. Randomized comparison of the effects of a very low calorie diet (Modifast™) and conventional dietary treatment on weight loss and risk parameters for atherosclerosis in obese outpatients [in German]. Aktuelle Ernahrung Klin Prax 1996;21:93-7 (48 weeks).
  174. Bertram SR, Venter I, Stewart RI. Weight loss in obese women -exercise v. dietary education. S Afr Med J 1990;78:15-18 (no 12-month weight data by treatment group).
  175. Blacket RB, Leelarthaepin B, McGilchrist CA, Palmer AJ, Woodhill JM. The synergistic effect of weight loss and changes in dietary lipids on the serum cholesterol of obese men with hypercholesterolaemia: implications for the prevention of coronary heart disease. Aust N Z J Med 1979;9:521-9 (BMI not ≥ 28 kg/m
  176. Bloemberg BP, Kromhout D, Goddijn HE, Jansen A, Obermann-de Boer GL. The impact of the Guidelines for a Healthy Diet of The Netherlands Nutrition Council on total and high density lipoprotein cholesterol in hypercholesterolemic free-living men. Am J Epidemiol 1991;134:39-48 (BMI not ≥ 28 kg/m
  177. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose- related weight loss. Obes Res 1999;7:189-98 (30 weeks).
  178. Brightwell DR, Naylor CS. Effects of a combined behavioral and pharmacological program on weight loss. Int J Obes 1979;3:141-8 (24 weeks).
  179. Casebeer LL, Klapow JC, Centor RM, Stafford MA, Renkl LA, Mallinger AP, et al. An intervention to increase physicians' use of adherence-enhancing strategies in managing hypercholesterolemic patients. Acad Med 1999;74:1334-9 (9 months).
  180. Cox KL, Puddey IB, Burke V, Beilin LJ, Morton AR, Bettridge HF. Determinants of change in BP during SWEAT. The Sedentary Women Adherence Trial. Clin Exp Pharmacol Physiol 1996;23:567-9 (BMI not ≥ 28 kg/m
  181. Croft PR, Brigg D, Smith S, Harrison CB, Branthwaite A, Collins MF. How useful is weight reduction in the management of hypertension? J R Coll Gen Pract 1986; 36:445-8 (6 months).
  182. D'Eramo GA. A comparison of intensity of educational intervention on knowledge, attitude, weight and metabolic control in obese individuals with type II non- insulin dependent diabetes mellitus. Dissert Abstr Int 1988;49:43 (no 12-month weight data).
  183. Dengel DR, Hagberg JM, Coon PJ, Drinkwater DT, Goldberg AP. Effects of weight loss by diet alone or combined with aerobic exercise on body composition in older obese men. Metabolism 1994;43:867-71 (10 months).
  184. Doucet E, Imbeault P, Almeras N, Tremblay A. Physical activity and low-fat diet: is it enough to maintain weight stability in the reduced-obese individual following weight loss by drug therapy and energy restriction? Obes Res 1999;7:323-33 (37 weeks).
  185. Dramaix M, Kornitzer M, De Backer G, Thilly C, Kittel F, Graffar M. The Belgian Heart Disease Prevention Project [in French]. Rev Epidemiol Sante Publique 1981; 29:289-303 (no weight data).
  186. Foster GD, Wadden TA, Peterson FJ, Letizia KA, Bartlett SJ, Conill AM. A controlled comparison of three very-low-calorie diets: effects on weight, body composition, and symptoms. Am J Clin Nutr 1992; 55:811-17 (24 weeks).
  187. Georgiades A, Sherwood A, Gullette EC, Babyak MA, Hinderliter A, Waugh R, et al. Effects of exercise and weight loss on mental stress-induced cardiovascular responses in individuals with high blood pressure. Hypertension 2000;36:171-6 (6 months).
  188. Gosselin P, Verreault R, Gaudreault C, Guillemette J. Dietary treatment of mild to moderate hypercholesterolemia. Effectiveness of different interventions [in French]. Can Fam Physician 1996; 42:2160-7 (6 months).
  189. Grimm RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997;29:8-14 (weight advice not randomised between groups).
  190. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90 (BMI not ≥ 28 kg/m 2 ).
  191. Hellenius ML, Krakau I, de Faire U. Favourable long- term effects from advice on diet and exercise given to healthy men with raised cardiovascular risk factors. Nutr Metab Cardiovasc Dis 1997;7:293-300 (BMI not ≥ 28 kg/m
  192. Hermann LS, Kjellstrom T, Nilsson EP. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non- insulin-dependent diabetes mellitus. Diabetes Metab 1991;17:174-9 (6 months).
  193. Hermann LS, Kjellstrom T, Schersten B, Lindgarde F, Bitzen P, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994;17:1100-9 (24 weeks).
  194. Kanders B, Jones CT, Smits G, McPhie A, Lavin P, Blackburn G. Comparison of two diets in a 27-week randomised trial: changes in body weight and blood pressure in a population of obese hypertensives. Int J Obes 1989;13:399 (abstract only).
  195. Krachler M, Lindschinger M, Eber B, Watzinger N, Wallner S. Trace elements in coronary heart disease: impact of intensified lifestyle modification. Biol Trace Elem Res 1997;60:175-85 (BMI not ≥ 28 kg/m
  196. Kraslin HA. A comparative study of three weight loss programs: physical exercise, psychoeducation, and combined physical exercise/psychoeducation. Dissert Abstr Int 1990;50:1988 (26 weeks).
  197. Krinick GB. Evaluation of weight resistance training as a component of exercise in the behavioral treatment of obesity. Dissert Abstr Int B Sci Eng 2000;61:1066 (24 weeks).
  198. LaRosa JC, Cleary P, Muesing RA, Gorman P, Hellerstein HK, Naughton J. Effect of long-term moderate physical exercise on plasma lipoproteins. The National Exercise and Heart Disease Project. Arch Intern Med 1982;142:2269-74 (subgroup of main trial National Exercise and Heart Disease Project; BMI not ≥ 28 kg/m 2 ).
  199. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional- hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91:698-706 (weight advice not randomised between groups).
  200. Lisspers J, Sundin O, Hofman-Bang C, Nordlander R, Nygren A, Ryden L, et al. Behavioral effects of a comprehensive, multifactorial program for lifestyle change after percutaneous transluminal coronary angioplasty: a prospective, randomized controlled study. J Psychosom Res 1999;46:143-54 (?BMI ≥ 28 kg/m

200 of 267 shown

Cited by

Sorted by citations

Related

Authors
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A.
Affiliations
  • University of Aberdeen (GB)
  • NHS Grampian (GB)
  • NHS Tayside (GB)
ORCID
Venue
Health Technology Assessment
Publisher
National Institute for Health and Care Research
Published
2004-05
Volume
8
Issue
21
Pages
iii-iv, 1
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
DOI
10.3310/hta8210
OpenAlex
W2098590161
Cited by
1,041
References
614
Citations by year
2026: 7 · 2025: 9 · 2024: 37 · 2023: 21 · 2022: 28 · 2021: 25 · 2020: 36 · 2019: 41 · 2018: 41 · 2017: 50 · 2016: 56 · 2015: 58 · 2014: 61 · 2013: 74 · 2012: 58
FWCI
5.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Teesside University Research Portal (Teesside University) (submittedVersion)
Funders
Health Technology Assessment programme (99/02/02)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
long-term weight loss, orlistat, sibutramine, metformin, type 2 diabetes prevention, bariatric surgery, low-fat diet, exercise therapy, behavior therapy, family therapy, impaired glucose tolerance, cost-effectiveness, quality-adjusted life years, cardiovascular disease, hypertension, LDL cholesterol, mortality, economic burden of obesity, very low calorie diet
MeSH terms
Orlistat, Behavior Therapy, Cost-Benefit Analysis, Cyclobutanes, Humans, Hypoglycemic Agents, Lactones, Markov Chains, Metformin, Obesity, Physical Fitness, Risk Factors, Randomized Controlled Trials as Topic, Diet, Fat-Restricted, Anti-Obesity Agents, Caloric Restriction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review